Germany, Spain, and Italy conduct well-documented hypertension stem-cell trials within university cardiovascular departments. Poland and Czech Republic offer active protocols at lower cost. South Korea maintains several recruiting hypertension trials. United States capacity is fragmented; cardiovascular research centres at major academic medical centres conduct some MSC-hypertension trials. Brazil and several Latin American countries have active programmes. Selection should prioritise centres with cardiovascular-imaging capabilities, published safety data, and ClinicalTrials.gov registration over claims of guaranteed blood-pressure reduction.
Arterial hypertension stem-cell treatment costs typically range €3,500–6,500 per infusion, depending on cell source and formulation. Exosome-based therapies, when offered, may cost similarly to MSCs or slightly higher due to manufacturing complexity. Single-infusion protocols are more common in hypertension than multi-cycle regimens, potentially reducing total expense compared to other conditions. Placental MSCs are favoured for cost-efficiency and cardiovascular safety profile. Home-based blood-pressure monitoring adds minimal cost but is essential for outcome assessment. European hospital-affiliated programmes typically charge €3,500–5,000; private cardiovascular clinics may exceed €6,500. Insurance rarely covers experimental therapy, necessitating out-of-pocket payment.
Am I a candidate? → · Arterial Hypertension: full overview → · Arterial Hypertension cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita